The Biosafety (Contained Use) Regulations

These Regulations may be cited as the Biosafety (Contained Use) Regulations.

AI-assisted research synopsis — verify against the official legal text below.

Jurisdiction: Kenya
Instrument: Notice
Citation: Legal Notice 96 of 2011
Version: Undated source snapshot
Language: en

Source attribution: Source: Kenya Law

Statute overview

About this statute

These Regulations may be cited as the Biosafety (Contained Use) Regulations. Defines/identifies in-vitro nucleic acid techniques including recombinant DNA use and direct injection of nucleic acid into cells or organelles. The Regulations aim to ensure potential adverse effects of genetically modified organisms are addressed to protect human health and the environment during contained use. Exceptions for genetically modified organisms that are pharmaceuticals for human use. Grantees must submit quarterly reports on progress during the approved activity period.

Read the provisions Ask with citations

Search within this statute

Search all stored provisions in this version.

Legal text

Provisions of The Biosafety (Contained Use) Regulations

Showing 21 of 21

Part I

PRELIMINARY

1
PRELIMINARY - 1. Citation

AI-assisted research summary: These Regulations may be cited as the Biosafety (Contained Use) Regulations.

Section 1. Citation Section These Regulations may be cited as the Biosafety (Contained Use) Regulations.
2
PRELIMINARY - 2. Interpretation

AI-assisted research summary: Defines/identifies in-vitro nucleic acid techniques including recombinant DNA use and direct injection of nucleic acid into cells or organelles.

Section 2. Interpretation Section in-vitro nucleic acid techniques including the use of recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles; or
3
PRELIMINARY - 3. Objective

AI-assisted research summary: The Regulations aim to ensure potential adverse effects of genetically modified organisms are addressed to protect human health and the environment during contained use.

Section 3. Objective Section The objective of these Regulations is to ensure that potential adverse effects of genetically modified organisms are addressed to protect human health and the environment when conducting contained use.
4
PRELIMINARY - 4. Exceptions

AI-assisted research summary: Exceptions for genetically modified organisms that are pharmaceuticals for human use.

Section 4. Exceptions Section to genetically modified organisms which are pharmaceuticals for human use;

Part II

CONTAINMENT MEASURES

10
CONTAINMENT MEASURES - 10. Validity of the approved activity

AI-assisted research summary: Grantees must submit quarterly reports on progress during the approved activity period.

Section 10. Validity of the approved activity Section 10(1) An approval under these Regulations shall be for the period of the activity. Section 10(2) A grantee under these Regulations shall submit quarterly reports on the progress of the activity during the period of the approved activity.
11
CONTAINMENT MEASURES - 11. Suspension or revocation of approval

AI-assisted research summary: The Authority may suspend or revoke approvals if a grantee breaches the Regulations; before doing so it must give written notice to the grantee to implement containment or other protective measures.

Section 11. Suspension or revocation of approval Section 11(1) The Authority may suspend or revoke an approval granted under these Regulations, where the grantee is in contravention of the provisions of these Regulations. Section 11(2) The Authority shall, before suspending or revoking an approval, give a written notice to the grantee to put in place such appropriate containment measures or other protective measures.
12
CONTAINMENT MEASURES - 12. Handling of new information

AI-assisted research summary: Grantees must inform the Authority as soon as possible of new information that could significantly affect risk; withholding such information is an offence punishable by a fine up to two million shillings or imprisonment up to ten years; the Authority may require modification, suspension or termination of contained use and must follow time limits for acknowledging requests and communicating decisions.

Section 12. Handling of new information Section 12(1) A grantee who subsequently becomes aware of information which could have significant consequences for the risks posed by it, shall inform the Authority of such information as soon as possible. Section 12(2) A person who withholds any information that becomes available before and after the approval of the application, and which could reasonably be expected to change the evaluation of the risk posed by the activity, commits an offence and is liable on conviction to a fine not exceeding two million shillings or imprisonment for a term not exceeding ten years, or both. Section 12(3) Where information which could have significant consequences for the risks posed by the contained use, subsequently becomes available, the Authority may require the grantee to modify the conditions of, or suspend or terminate, the contained use. Section 12(4) A grantee, who wishes to request for an extension or to modify the contained use, may make a written request to the Authority and the Authority shall within thirty days acknowledge receipt of the request. Section 12(5)(a) does not require risk assessment, the Authority shall communicate its decision within thirty days from the date of the receipt of the request; or Section 12(5)(b) may have material effect on the outcome of the risk assessment upon which the decision was based, the Authority shall, if is satisfied that a change is warranted, make a decision within one hundred days from the date of the receipt of the request.
13
CONTAINMENT MEASURES - 13. Contingency plans

AI-assisted research summary: The applicant must draw up a contingency plan for contained use to mitigate risks to people outside the premises or to the environment resulting from failure of containment measures.

Section 13. Contingency plans Section the applicant draws up a contingency plan for contained use to mitigate against risk, whether immediate or delayed, to humans outside the premises or to the environment as a result of failure of the contained use measures;
14
CONTAINMENT MEASURES - 14. Contents of contingency plans

AI-assisted research summary: Every contingency plan shall be in the form set out in the Fifth Schedule.

Section 14. Contents of contingency plans Section Every contingency plan shall be in the form set out in the Fifth Schedule.
15
CONTAINMENT MEASURES - 15. Emergency measures

AI-assisted research summary: A person who contravenes subregulation (1) commits an offence.

Section 15. Emergency measures Section 15(1)(a) the circumstances and location of the accident; Section 15(1)(b) the identity and quantities of the genetically modified organisms; Section 15(1)(c) any information necessary to assess the effects of the accident on human beings, and the environment; and Section 15(1)(d) the measures taken to mitigate against risk. Section 15(2)(a) ensure that necessary measures are taken to control the effects of the accident; Section 15(2)(b) where possible, collect, information necessary for a full analysis of the accident; and Section 15(2)(c) where appropriate, make recommendations on how to avoid a similar accident in the future and to limit the effects thereof. Section 15(3) A person who contravenes subregulation (1) commits an offence.
5
CONTAINMENT MEASURES - 5. Classification of containment levels

AI-assisted research summary: The Authority must ensure appropriate measures to prevent adverse effects from the contained use of genetically modified organisms and must assess premises, determine containment levels with the relevant regulatory agency, and develop procedures for confined field trials in consultation with that agency.

Section 5. Classification of containment levels Section 5(1) The Authority shall ensure that all appropriate measures are taken to avoid adverse effects on human health and the environment, which might arise from the contained use of a genetically modified organism. Section 5(2) The Authority in consultation with the relevant regulatory agency shall assess the suitability of a contained use premises to conduct contained use activity involving genetically modified organism. Section 5(3) Upon carrying out the assessment, the Authority in consultation with the relevant regulatory agency shall determine the containment level of the contained use premises in accordance with the provisions of the Second Schedule. Section 5(4) The containment levels under this Regulation apply to laboratory, greenhouse or screen house activities. Section 5(5) Appropriate measures for confined field trials shall be determined through procedures developed by the Authority in consultation with the relevant Regulatory Agency.
6
CONTAINMENT MEASURES - 6. Institutional Biosafety Committee

AI-assisted research summary: Research institutions undertaking contained use activities must establish an Institutional Biosafety Committee; the Committee has specified functions; individuals must not carry out contained use activities outside such institutions or collaborations.

Section 6. Institutional Biosafety Committee Section 6(1) A research institution undertaking contained use activities shall establish an Institutional Biosafety Committee. Section 6(2)(a) biosafety officer(s); Section 6(2)(b) scientist(s) in the relevant field; Section 6(2)(c) representative(s) of technical staff; Section 6(2)(d) representative(s) of laboratory management; Section 6(2)(e) representative(s) of the community where the premises are situated; and Section 6(2)(f) representative(s) of the relevant regulatory agency. Section 6(3)(a) to prepare applications for contained use activities and refer the applications to the Authority for approval; Section 6(3)(b) to advise the research institution on matters relating to biosafety; Section 6(3)(c) to assist the institution in the establishment of the appropriate monitoring mechanisms for risk assessments and risk management; Section 6(3)(d) to ensure compliance with the conditions set out in the approval; Section 6(3)(e) to review and ascertain the suitability of both physical and biological containment and control procedures appropriate to the level of assessed risk involved in research, development and application activities; Section 6(3)(f) to advice the institution and principal investigators on mitigation measures to be undertaken in case of an accident. Section 6(4) A person shall not carry out contained use activity under these Regulations unless such activity is carried out within, or in collaboration with, a research institution. Section 6(5) A person who contravenes sub regulation (4) commits an offence.
7
CONTAINMENT MEASURES - 7. Application for contained use

AI-assisted research summary: Persons must not undertake contained use without the written approval of the Authority. Applications for contained use must be made to the Authority through an Institutional Biosafety Committee, use the form in the Third Schedule, and be accompanied by an application fee of one hundred and seventy thousand shillings. Contravention of the prohibition is an offence.

Section 7. Application for contained use Section 7(1) A person shall not undertake contained use without the written approval of the Authority. Section 7(2) An application for contained use shall be made to the Authority through an Institutional Biosafety Committee. Section 7(3) An application for contained use shall be in the form set out in the Third Schedule to these Regulations and shall be accompanied by an application fee of one hundred and seventy thousand shillings. Section 7(4) A person who contravenes subregulation (1) commits an offence.
8
CONTAINMENT MEASURES - 8. Consideration of application

AI-assisted research summary: The Authority must screen applications for completeness, circulate them to relevant regulatory agencies, may require further information or modifications, and must communicate a final decision between ninety and one hundred and fifty days after receipt.

Section 8. Consideration of application Section 8(1) Upon receipt of an application under regulation 7, the Authority shall screen for completeness and circulate the application to the relevant regulatory agencies for further information, comments or reasoned objections. Section 8(2)(a) that the application conforms with the requirements of these Regulations; Section 8(2)(b) the accuracy and completeness of the information given; Section 8(2)(c) the risk assessment submitted by the applicant; Section 8(2)(d) the level of contained uses; and Section 8(2)(e) where appropriate, the suitability of the containment and other protective measures, the waste management, and contingency measures. Section 8(3)(a) require the applicant to provide further information; or Section 8(3)(b) require the applicant to modify the conditions of the proposed contained use, or to amend the level assigned to the contained use; or Section 8(3)(c) limit the time for which the contained use should be permitted or subject it to certain specific conditions. Section 8(4) The Authority shall communicate its final decision within one hundred and fifty days of receipt of the application but not earlier than ninety days of such receipt. Section 8(5) For the purpose of calculating time, any period of time during which the Authority is awaiting any further information that it may have requested from the applicant shall not be taken into account.
9
CONTAINMENT MEASURES - 9. Approval

AI-assisted research summary: Approvals for contained use must follow the Fourth Schedule form, are valid for the period of the activity for which they are granted, and are not transferable.

Section 9. Approval Section 9(1) An approval for contained use shall be in the form set out in the Fourth Schedule. Section 9(2) An approval granted under these Regulations shall be valid for the period of the activity in respect of which it is granted. Section 9(3) An approval for contained use is not transferable.

Part III

MISCELLANEOUS

16
MISCELLANEOUS - 16. Information sharing and records

AI-assisted research summary: Section 16 lists information maintained in the register, provides that the register is open for inspection on payment of an inspection fee of five hundred shillings, and requires the Authority to establish a procedure for exchanging information and experiences.

Section 16. Information sharing and records Section 16(1)(a) application; Section 16(1)(a)(i) application; Section 16(1)(a)(ii) risk assessment document; Section 16(1)(a)(iii) decision document; Section 16(1)(a)(iv) approval document; and Section 16(1)(a)(v) contingency plan; Section 16(1)(b) a list of institutional biosafety committees; and Section 16(1)(c) any other information that the Authority may deem necessary. Section 16(2) The register shall be open for inspection by any interested person upon payment of an inspection fee of five hundred shillings. Section 16(3) The Authority shall establish a procedure for the exchange of information and experiences gained.
17
MISCELLANEOUS - 17. Registration of decisions in the National Biosafety Clearing House

AI-assisted research summary: The Authority must register all decisions made under these Regulations in the National Biosafety Clearing House within thirty days of making the decision.

Section 17. Registration of decisions in the National Biosafety Clearing House Section The Authority shall register all decisions made under these Regulations in the National Biosafety Clearing House within thirty days of making the decision.
18
MISCELLANEOUS - 18. Confidential information

AI-assisted research summary: Applicants may request that certain application information be kept confidential and must give reasons; the Authority decides confidentiality, informs the applicant in writing, protects applicants' intellectual property rights, and must keep information confidential if an applicant withdraws.

Section 18. Confidential information Section 18(1) An applicant may request that certain information in his application be treated as confidential and shall give reasons for the request. Section 18(2) The Authority shall determine if the information should be kept confidential and shall communicate its decision to the applicant in writing. Section 18(3)(a) name and address of the applicant; Section 18(3)(b) the general characteristics of the genetically modified organism; Section 18(3)(c) class of contained use and measures of containment; and Section 18(3)(d) the evaluation of foreseeable effects, in particular any harmful effects on human health and the environment. Section 18(4) The authority shall protect the intellectual property rights of the applicant. Section 18(5) Where an applicant withdraws an application, the Authority shall maintain confidentiality on the information supplied.
19
MISCELLANEOUS - 19. Good containment measures

AI-assisted research summary: An applicant must apply the general principles and appropriate containment and protective measures in Part II of the Second Schedule that correspond to the class of the contained use.

Section 19. Good containment measures Section An applicant shall apply the general principles and the appropriate containment and other protective measures set out in Part II of the Second Schedule to these Regulations corresponding to the class of the contained use.
20
MISCELLANEOUS - 20. Handling of modified plasmids and vectors

AI-assisted research summary: Modified plasmids or vectors used as tools for modern biotechnology must be approved by the relevant regulatory agency.

Section 20. Handling of modified plasmids and vectors Section Modified plasmids or vectors used as tools for modern biotechnology shall be approved by the relevant regulatory agency.
21
MISCELLANEOUS - 21. Penalties

AI-assisted research summary: A person who contravenes these Regulations commits an offence and on conviction may be fined up to twenty million shillings or imprisoned for up to ten years, or both.

Section 21. Penalties Section A person who contravenes any of the provisions of these Regulations commits an offence and is liable on conviction to a fine not exceeding twenty million shillings or to imprisonment for a term not exceeding ten years, or both.

Provision text is displayed from LexChat’s stored statute record. Use the official source links to verify amendments, commencement, and current legal force.

About this LexChat collection

Publisher and coverage

LexChat is published by Esheria. Coverage reflects the legislation currently mapped from identified source collections; it may be incomplete, delayed, or later corrected. The official source controls where it differs from this research page.

AI and research method

AI-generated material is explicitly labelled and published only through LexChat's quality controls. It is a research aid, not the source document.

Corrections and reporting

Report a source mismatch, factual issue, personal-data concern, or licensing question to support@esheria.co.ke. Include this page's URL and the supporting official source so the record can be reviewed, corrected, restricted, or withdrawn.

Legal-information disclaimer

LexChat provides legal information and research tools, not legal advice. Verify currency, status, citations, and jurisdiction with authoritative sources and a qualified professional where appropriate.